686 related articles for article (PubMed ID: 18082496)
1. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
Serebruany VL; Malinin AI; Pokov A; Barsness G; Hanley DF
Am Heart J; 2008 Jan; 155(1):93.e1-7. PubMed ID: 18082496
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
3. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
4. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
Serebruany VL; Malinin AI; Ziai W; Pokov AN; Bhatt DL; Alberts MJ; Hanley DF
Stroke; 2005 Oct; 36(10):2289-92. PubMed ID: 16151033
[TBL] [Abstract][Full Text] [Related]
5. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
Serebruany V; Pokov I; Kuliczkowski W; Chesebro J; Badimon J
Thromb Haemost; 2008 Jul; 100(1):76-82. PubMed ID: 18612541
[TBL] [Abstract][Full Text] [Related]
6. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
[TBL] [Abstract][Full Text] [Related]
7. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
[TBL] [Abstract][Full Text] [Related]
8. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
[TBL] [Abstract][Full Text] [Related]
9. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
[TBL] [Abstract][Full Text] [Related]
10. Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
Li J; Jian Z; Huang L; Guo H; Huang J; Qian D; Fu W; Li A; Song Y
Biomed Pharmacother; 2009 Sep; 63(8):608-12. PubMed ID: 19019624
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
[TBL] [Abstract][Full Text] [Related]
13. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
Tetik S; Ak K; Isbir S; Eksioglu-Demiralp E; Arsan S; Iqbal O; Yardimci T
Clin Appl Thromb Hemost; 2010 Apr; 16(2):189-98. PubMed ID: 19703819
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
[TBL] [Abstract][Full Text] [Related]
16. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
[TBL] [Abstract][Full Text] [Related]
17. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
18. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Cooke GE; Liu-Stratton Y; Ferketich AK; Moeschberger ML; Frid DJ; Magorien RD; Bray PF; Binkley PF; Goldschmidt-Clermont PJ
J Am Coll Cardiol; 2006 Feb; 47(3):541-6. PubMed ID: 16458133
[TBL] [Abstract][Full Text] [Related]
19. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.
Serebruany VL; Malinin AI; Atar D; Hanley DF
Am Heart J; 2007 Mar; 153(3):371-7. PubMed ID: 17307414
[TBL] [Abstract][Full Text] [Related]
20. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
